The clinical course of the present case suggested that RANKL-RANK signaling may be a key pathological mechanism in establishment or development of NAFLD or NASH in patients with panhypopituitarism including GHD. Here, TNFRSF11A is linked to metabolic dysfunction-associated steatotic liver disease.